A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Relapse/Refractory Multiple Myeloma Clinical Trial

Official title:

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06084962
• Other study ID #: TXB2023018
• Status: Recruiting
• Phase: Phase 1
• Start date: October 20, 2023
• Est. completion date: October 20, 2026

Study information

• Verified date: September 2023
• Source: Zhejiang University
• Contact: He Huang, MD
• Phone: 86-13605714822
• Email: hehuangyu[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma

Description:

In this study, 60 patients with relapsed refractory multiple myeloma were proposed to undergo DeepTag-GPRC5D CAR-T cell therapy. Under the premise that its safety has been clarified in previous studies, further observation and evaluation of the effectiveness of DeepTag-GPRC5D CAR-T cell therapy for relapsed refractory multiple myeloma; At the same time, on the basis of expanding the sample size, more safety data on DeepTag-GPRC5D CAR-T cell treatment for relapsed refractory multiple myeloma were accumulated, including rare and delayed complications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: October 20, 2026
• Est. primary completion date: October 20, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1. Those who voluntarily participated in this trial and provided informed consent;
• 2. Gender unlimited,18<Age=75;
• 3. Estimated life expectancy of minimum of 12 weeks;
• 4. ECOG 0-2;
• 5. Diagnosed as multiple myeloma according to the IMWG criteria;
• 6. Subjects failed treatment with at least 3 prior lines of therapy (including chemotherapy based on proteasome inhibitors (PIs) ,immunomodulatory agents (IMiDs) and CD38 antibody), or recived the above three treatment methods experienced disease progression or recurrence during the most recent treatment process or within 6 months after the end of treatment, Difficulty in treatment includes primary difficulty in treatment ( patient has not achieved minimal remission or disease progression during treatment) or secondary difficulty in treatment (patient develops disease progression within 60 days after completion of treatment);
• 7. Women have a negative urine pregnancy test before the start of medication administration and agree to take effective contraceptive measures during the trial period until the last follow-up;
• 8. The blood routine meets the following standards:

1. Lymphocyte count>0.3×10e9/L;

2. Neutrophils =0.5×10e9/L;

3. Hemoglobin =60g/L;

4. Platelet =30×10e9/L

Exclusion Criteria:

• 1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
• 2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
• 3. Pregnant (or lactating) women;
• 4. Patients with HIV infection;
• 5. Active infection of hepatitis B virus or hepatitis C virus;
• 6. Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids;
• 7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
• 8. Creatinine>2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin>2.0 mg/dl;
• 9. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study;
• 10. Patients who received anti-cancer chemotherapy or other medications within 2 weeks before screening;
• 11. Uncontrolled malignant tumors except MM, excluding malignant tumors that received radical treatment and no active disease was found within 3 years before enrollment;
• 12. Patients who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks before screening, or who plan to undergo ASCT during the study period;
• 13. Patients received allogeneic stem cell therapy;
• 14. Any unsuitable to participate in this trial judged by the investigator.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapse/Refractory Multiple Myeloma

Intervention

Biological:
• DeepTag-GPRC5D Targeted CAR T-cells
Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion

Locations

Country	Name	City	State
China	The first affiliated hospital of medical college of zhejiang university	Hangzhou	Zhejiang

Sponsors (2)

Lead Sponsor	Collaborator
He Huang	Yake Biotechnology Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity (DLT)	Adverse events assessed according to NCI-CTCAE v5.0 criteria	Up to 28 years after Treatment
Primary	Incidence of treatment-emergent adverse events (TEAEs)	Incidence of treatment-emergent adverse events [Safety and Tolerability]	Up to 2 years after Treatment
Secondary	Multiple Myeloma (MM), Overall response rate (ORR)	Assessment of ORR (ORR = sCR+CR+VGPR+PR+MR)	Up to 2 years after Treatment
Secondary	Progression-free survival (PFS)	The time from randomization or start of study treatment until objective tumor progression or death	Up to 2 years after Treatment
Secondary	Duration of remission,DOR	The time from CR/CRi and PR to disease relapsed or death due to disease	Up to 1 years after Treatment